The liver is the sixth most common site of primary cancer in humans and the fourth leading
cause of cancer‐related death in the world. Hepatocellular carcinoma (HCC) accounts for …

Hepatocellular carcinoma (HCC) is an aggressive human cancer with increasing incidence
worldwide. Multiple efforts have been made to explore pharmaceutical therapies to treat …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the
fourth most common malignancy and the second leading cause of tumor-related death …

PURPOSE Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative,
has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study …

2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates
and insights - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Background Systemic therapies have improved the management of hepatocellular
carcinoma, but there is still a need to further enhance overall survival in first-line advanced …

Background Blocking the interaction between PD-1 and its ligands is a promising treatment
strategy for advanced hepatocellular carcinoma. This study aimed to assess the antitumour …

Summary In 2010, modified RECIST (mRECIST) criteria were proposed as a way of
adapting the RECIST criteria to the particularities of hepatocellular carcinoma (HCC). We …

Background Inhibition of vascular endothelial growth factor receptor (VEGFR) has shown
antitumour activity in advanced hepatocellular carcinoma, but few studies of VEGFR …